Cara A. Rosenbaum

3.3k total citations
46 papers, 441 citations indexed

About

Cara A. Rosenbaum is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Cara A. Rosenbaum has authored 46 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 27 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Cara A. Rosenbaum's work include Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (17 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Cara A. Rosenbaum is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (17 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Cara A. Rosenbaum collaborates with scholars based in United States, Canada and Poland. Cara A. Rosenbaum's co-authors include Todd M. Zimmerman, Andrzej Jakubowiak, Paul G. Richardson, Ajai Chari, Jagoda Jasielec, Jennifer Nam, Jesús G. Berdeja, Shaun Rosebeck, Noopur Raje and Jeffrey A. Zonder and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cara A. Rosenbaum

41 papers receiving 433 citations

Peers

Countries citing papers authored by Cara A. Rosenbaum

Since Specialization

Citations

This map shows the geographic impact of Cara A. Rosenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cara A. Rosenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cara A. Rosenbaum more than expected).

Fields of papers citing papers by Cara A. Rosenbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cara A. Rosenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cara A. Rosenbaum. The network helps show where Cara A. Rosenbaum may publish in the future.

Co-authorship network of co-authors of Cara A. Rosenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Cara A. Rosenbaum. A scholar is included among the top collaborators of Cara A. Rosenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cara A. Rosenbaum. Cara A. Rosenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma 2024 ·Blood Advances ·Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung, Barbara Grant, Cara A. Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard	2
2	Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis 2023 ·ClinicoEconomics and Outcomes Research ·Morie A. Gertz, Rafat Abonour, Sarah N. Gibbs, (unknown), Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany P. Quock, Cara A. Rosenbaum, Michael Rosenzweig, Surbhi Sidana, Sascha A. Tuchman, Ronald Witteles, Irina Yermilov, Michael S. Broder	0
3	Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab 2023 ·Blood ·Cara A. Rosenbaum, Michaela Liedtke, Paul J. Christos, Hye Min Kim, (unknown), (unknown), (unknown), Anthony C Shelton, Samantha M. Reilly, (unknown), J. Mark Sloan, Vaishali Sanchorawala, Anita D’Souza	1
4	First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara–VCD front‐line therapy 2023 ·British Journal of Haematology ·Rajshekhar Chakraborty, Cara A. Rosenbaum, Gurbakhash Kaur, Divaya Bhutani, Jai Radhakrishnan, Markus Y. Mapara, Matthew J. Maurer, Suzanne Lentzsch	15
5	Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database. 2023 ·Journal of Clinical Oncology ·(unknown), David Jayabalan, (unknown), (unknown), Cara A. Rosenbaum, Roger Pearse, Rubén Niesvizky, (unknown), Mark Bustoros	2
6	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance 2022 ·Frontiers in Oncology ·(unknown), (unknown), David Jayabalan, Jorge Monge, Cara A. Rosenbaum, Roger Pearse, Rubén Niesvizky, Mark Bustoros	7
7	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial 2021 ·SHILAP Revista de lepidopterología ·Noa Biran, Binod Dhakal, Suzanne Lentzsch, David S. Siegel, Saad Z. Usmani, Adriana Rossi, Cara A. Rosenbaum, Divaya Bhutani, David H. Vesole, Cesar Rodriguez, Ajay K. Nooka, Frits van Rhee, Lisette Stork‐Sloots, Femke De Snoo, Pritish K. Bhattacharyya, Durga Prasad Dash, (unknown), Martin H. van Vliet, Parameswaran Hari, Rubén Niesvizky	9
8	Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma 2019 ·Blood ·Cara A. Rosenbaum, Danny Luan, Paul J. Christos, Roger Pearse, (unknown), Morton Coleman, Koen van Besien, Rubén Niesvizky	0
9	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS). 2019 ·Journal of Clinical Oncology ·Parameswaran Hari, Suzanne Lentzsch, David S. Siegel, Saad Z. Usmani, Binod Dhakal, Adriana Rossi, Cara A. Rosenbaum, Siyang Leng, Divaya Bhutani, Noa Biran, David H. Vesole, Manisha Bhutani, Lisette Stork‐Sloots, Femke De Snoo, (unknown), M. van Vliet, Rubén Niesvizky	2
10	Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma 2019 ·British Journal of Haematology ·Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Craig E. Cole, Ajai Chari, Joseph Mıkhael, Jennifer Nam, (unknown), (unknown), (unknown), (unknown), Shaun Rosebeck, Todd M. Zimmerman, (unknown), (unknown), Theodore Karrison, Jeffrey A. Zonder	55
11	Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study. 2019 ·Journal of Clinical Oncology ·María‐Victoria Mateos, Heinz Ludwig, Shaji Kumar, Cara A. Rosenbaum, Mei Huang, Amanda Goldrick, Julie Blædel, Meletios Α. Dimopoulos	0
12	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) 2016 ·Blood ·Todd M. Zimmerman, Noopur Raje, Ravi Vij, Donna Reece, Jesús G. Berdeja, (unknown), Kathryn McDonnell, Cara A. Rosenbaum, Jagoda Jasielec, Paul G. Richardson, Sandeep Gurbuxani, Jennifer Nam, (unknown), (unknown), Shaun Rosebeck, Andrew Stefka, Dominik Dytfeld, Kent A. Griffith, Andrzej Jakubowiak	41
13	Pilot Study of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Gottfried von Keudell, Cara A. Rosenbaum, Todd M. Zimmerman, Michael R. Bishop, Koen van Besien, (unknown), Amittha Wickrema, Andrzej Jakubowiak, Justin Kline	2
14	Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study 2014 ·Blood ·Cara A. Rosenbaum, Vishal Kukreti, Jeffrey A. Zonder, Daniel Lebovic, Todd M. Zimmerman, Jesús G. Berdeja, Kathryn McDonnell, (unknown), Kent A. Griffith, Andrzej Jakubowiak	5
15	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma 2013 ·Journal for ImmunoTherapy of Cancer ·Daniel M. Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, Mebea Aklilu, Daniel V.T. Catenacci, Blasé N. Polite, Cara A. Rosenbaum, Azadeh Namakydoust, Theodore Karrison, Thomas F. Gajewski, Hedy L. Kindler	33
16	Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma 2013 ·Blood ·Gottfried von Keudell, Cara A. Rosenbaum, Todd M. Zimmerman, Michael R. Bishop, Koen van Besien, (unknown), Amittha Wickrema, Andrzej Jakubowiak, Justin Kline	2
17	Evolving Strategies in the Initial Treatment of Multiple Myeloma 2013 ·Seminars in Oncology ·Cara A. Rosenbaum, Jagoda Jasielec, Jacob P. Laubach, (unknown), Paul G. Richardson, Andrzej Jakubowiak	5
18	Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study. 2012 ·Blood ·Shaji Kumar, Amrita Krishnan, Vivek Roy, Todd M. Zimmerman, Morie A. Gertz, Keith Stockerl‐Goldstein, Francis K. Buadi, Cara A. Rosenbaum, (unknown), Mark A. Fiala, (unknown), (unknown), Michael N. Needle, Ravi Vij	1
19	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC). 2012 ·Journal of Clinical Oncology ·Daniel M. Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, Mebea Aklilu, Daniel Virgil Thomas Catenacci, Blasé N. Polite, Cara A. Rosenbaum, Azadeh Namakydoust, Theodore Karrison, Thomas F. Gajewski, Hedy L. Kindler	1
20	Granulocyte Colony-Stimulating Factor-Based Stem Cell Mobilization in Patients with Sickle Cell Disease 2008 ·Biology of Blood and Marrow Transplantation ·Cara A. Rosenbaum, David Peace, Elizabeth Rich, Koen van Besien	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact